Whalesbook
Glenmark Pharmaceuticals has launched the world's first nebulised, fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD). The groundbreaking treatment combines three essential medicines, simplifying patient care and enhancing lung function. Following this significant announcement, Glenmark's shares experienced a notable rise, highlighting strong investor confidence in this innovative respiratory solution.